Jump to content
Sclero Forums

Search the Community

Showing results for tags 'cellcept'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 4 results

  1. Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease (SSc-ILD). Significantly favorable transitions from both ground glass and lung fibrosis ILD patterns to normal lung were found in patients undergoing immunosuppressive treatment for Ssc-ILD. PubMed, Arthritis Rheumatol, 08/20/2019. (Also see Cyclophosphamide and Cellcept) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Long-term efficacy and tolerability of mycophenolate mofetil (MMF) therapy in diffuse scleroderma (dcSSc) skin disease. MMF was associated with a modest improvement in modified Rodnan skin score (mRSS) and was well tolerated in the treatment of dcSSc. PubMed, Int J rheumatologist Dis, 03/24/2017. (Also see Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Mycophenolate mofetil for scleroderma–related interstitial lung disease. Although this study does not provide evidence for equivalency to cyclophosphamide, its clear benefit in patient tolerability made MMF the preferred initial treatment in an arena with limited options. The Lancet Respiratory Medicine, 2016 Nov;4(11):e53. (Also see Pulmonary Fibrosis Treatments: Cellcept) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Mycophenolate mofetil (MMF) is an effective and safe option for the management of systemic sclerosis–associated interstitial lung disease (SSc–ILD). In patients with SSc–ILD with declining pulmonary function, MMF therapy was associated with stability for up to 36 months. PubMed, Clin Exp Rheumatol, 03/24/2016. (Also see Pulmonary Fibrosis Treatments: Cellcept) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...